Boron Uptake and Survival Analysis for Canine Hemangiosarcoma Cell Lines

Ryota Iwasaki published experimental data on boron neutron capture therapy (BNCT) for canine hemangiosarcoma. The dataset includes measurements of boronophenylalanine uptake via LAT1 transporters and clonogenic survival assays following neutron and X-ray irradiation across three cell lines (JuB2, Ud6, Re21). It was last updated on May 12, 2026, and is licensed under CC-BY-4.0.

Use Cases

• Modeling LAT1-mediated boron compound uptake based on fluorescence and spectrometry measurements.
• Calculating relative biological effectiveness (RBE) and compound biological effectiveness (CBE) values from survival fraction data.
• Comparing in vitro therapeutic potential of neutron irradiation versus X-rays across different canine cancer cell lines.
• Investigating the correlation between intracellular boron-10 accumulation and cytotoxicity enhancement.

Strengths

• Data includes results from three distinct canine hemangiosarcoma cell lines (JuB2, Ud6, Re21).
• Multiple analytical methods were used: fluorescence measurements, imaging, inductively coupled plasma–atomic emission spectrometry, and clonogenic assays.
• Specific CBE values are reported for each cell line: 2.60 (JuB2), 2.31 (Ud6), and 1.25 (Re21).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (1.2 MB), indicating a limited experimental scope.

Provenance

Source

Ryota Iwasaki via figshare

Collection Method

Experimental data from in vitro studies on canine hemangiosarcoma cell lines.

Freshness

Last updated 2026-05-12 05:42:49; freshness should be verified.